Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Search

JTI Receives Global Top Employer Award for Tenth Consecutive Year

Events by 2FIRSTS.ai
Jan.18.2024
JTI Receives Global Top Employer Award for Tenth Consecutive Year
JTI, the Japanese tobacco multinational, has been awarded the Global Top Employer accolade for a record-breaking tenth consecutive year.

According to a report by Financial Post, Japan Tobacco International (JTI) has once again been awarded the prestigious Global Top Employer Award, marking its consecutive tenth year of receiving this accolade. Only seventeen global companies have been recognized with this honor, one of them being JTI, whose branches in eleven countries have all achieved first place rankings.

 

References:
[1] JTI Awarded Global Top Employer for the 10th Consecutive Year
Also Read:
[1] JTI Plans to Enter Korean HNB Market in H1 2024
[2] Japan Tobacco International Raises Cigarette Prices in Romania
[3] JTI Korea Considers Entry into Korean E-cigarette Market
#Asia#Market#Japan#JTI#Global#Employment

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Eleventh session of the Conference of the Parties (COP11) to the WHO FCTC
Eleventh session of the Conference of the Parties (COP11) to the WHO FCTC
Malaysia's Perlis Customs seized more than 510,000 smuggled e-cigarettes, involving more than US$2.85 million
Malaysia's Perlis Customs seized more than 510,000 smuggled e-cigarettes, involving more than US$2.85 million
In August, Malaysia's Perlis Customs raided Kampung Kawlan, seizing 517,394 e-cig devices/accessories in a Padang Besar warehouse. Haul: over RM12m (≈US2.85m),unpaidtaxesRM2.6m(≈US620k); 19yo guard arrested. Probes: e-cigs for Thailand, arrived via KLIA, to cross border illegally (pickup/container truck or Kelantan if blocked). Case under 1967 Customs Act §133(1)(f): max RM500k (≈US$120k) fine/7yrs jail, or both.
Sep.22 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split
EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split
The European Union will abstain from voting at the upcoming 11th session of the WHO Framework Convention on Tobacco Control (COP11) in Geneva, following months of internal disagreement over how to regulate tobacco and nicotine products. The decision marks a rare and public fracture in EU health policy, reportedly driven by the European Commission’s hardline anti-tobacco stance.
Nov.18 by 2FIRSTS.ai
Tasmania, Australia Will Introduce New Laws Targeting Illegal Vape and Tobacco Retailers
Tasmania, Australia Will Introduce New Laws Targeting Illegal Vape and Tobacco Retailers
Tasmania will introduce new laws next year to tackle the illegal trade in tobacco and vapes. The legislation will strengthen penalties, allow inspectors to issue on-the-spot fines and shut down non-compliant retailers, and enhance coordination between police and health authorities.
Nov.11 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21
AIR’s Shisha Brand Al Fakher Launches New Pod-Based Vape in Germany, Touting Non-Ceramic Atomization Technology
AIR’s Shisha Brand Al Fakher Launches New Pod-Based Vape in Germany, Touting Non-Ceramic Atomization Technology
AIR’s shisha brand Al Fakher has launched its rechargeable pod-based vape Crown Switch in Germany, featuring Coldstream technology and claiming low-temperature vaporization without ceramic or metal heating elements. The device is now available on shisha-world, while AIR is simultaneously pushing ahead with its plan to go public on Nasdaq via a SPAC merger.
Nov.20 by 2FIRSTS.ai
Related Topics
News Company
Related Read
Malaysia's Perlis Customs seized more than 510,000 smuggled e-cigarettes, involving more than US$2.85 million
Malaysia's Perlis Customs seized more than 510,000 smuggled e-cigarettes, involving more than US$2.85 million
2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
2FIRSTS.ai
EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split
EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split
2FIRSTS.ai
Tasmania, Australia Will Introduce New Laws Targeting Illegal Vape and Tobacco Retailers
Tasmania, Australia Will Introduce New Laws Targeting Illegal Vape and Tobacco Retailers
2FIRSTS.ai
ceshi1111
ceshi1111
AIR’s Shisha Brand Al Fakher Launches New Pod-Based Vape in Germany, Touting Non-Ceramic Atomization Technology
AIR’s Shisha Brand Al Fakher Launches New Pod-Based Vape in Germany, Touting Non-Ceramic Atomization Technology
2FIRSTS.ai
FOLLOW US ON SOCIAL MEDIA
Contact: info@2firsts.com
Stay up to date.
Submit your email to receive weekly newsletter on the most relevant news of the e-cigarette industry.
© 2025 Shenzhen 2FIRSTS Technology Co.,Ltd. All Right Reserved.
2FIRSTS is only accessible to industry practitioners, researchers, media and other professionals. Access by minors is prohibited.
This website provides services to users outside the Chinese mainland. For Chinese mainland users, please visit https://cn.2firsts.com
English
English
中文